Patients undergoing surgery to implant a new type of blood bank can benefit from classic methods for providing a life span of around 10 years after surgery.

Researchers at Victoria University of Wellington have given two recipients of the first of a 10 million NIH grant a step closer towards realizing clinical trial results that could help patients get transplantable healthy blood.

The pilot study known as Integral Transplanted Human Pluripotent Cells (ITS-C) Experiments was initially funded by the National Heart Lung and Blood Institute New Innovator Program allowing researchers to gather the first experimental data from Stem Cell Therapy through two human growth and disease modeling studies. NOW President of the New Zealand Synchrotron Radiation Preclinical Team Professor Elliot Steinleit of the University of New England will formally present the research in a video to the United Synchrotron Radiation Committee Meeting in Tokyo Japan from Jan 11-13.

Along with the joy of seeing and working with Professor Steinleit I am especially honoured to be among the scientists who have been able to bring this important research to our once-encouraged surgical teams said Professor Steinleit. The invaluable contribution of Professor Steinleit and team has been a huge help in this pre-clinical trial process which has enabled us to unleash the potential of Stem Cell Therapy. And most importantly it has allowed us to study the potential of delivering TCS in a safer and easier-to-administer dose. Professor Steinleit is also heading New Zealands next generation treatment development phase of the NIH Clinical Trial Implementation Protocol (CTP) which will provide clinical trial results that have promise for patients who need. This trial will allow the investigators to test the trials methodology and its effectiveness at improving impact of bone marrow transplantation medicine in addition to the efficacy of now available TCS protocols.

This important research will provide hope to millions of people who suffer complications following bone marrow transplants said Prime Minister Jacinda Ardern.